Ultima-CJC-1295 DAC 2mg

Manufacturer: Ultima Pharmaceuticals

Pharmaceutical name: Modified GRF (1-29)

Pack: 1 vial (2 mg)

CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic version of a segment of naturally occurring growth hormone-releasing hormone (GHRH). The CJC-1295 with DAC peptide structure is built around the initial 29 amino acids of naturally produced GHRH, which are essential for full biological activity.

 

However, this peptide has been further enhanced by altering four amino acids to boost its stability and effectiveness compared to the original CJC-1295 without DAC. These modifications allow the peptide to attach permanently to the protein albumin in the body, thereby minimizing degradation and oxidation to enhance its stability. Additionally, these extra amino acids improve the binding strength to the GHRH receptor, increasing its potency. GHRH is crucial for the secretion of natural growth hormone and plays a vital role in achieving optimal growth during developmental stages.

 

CJC-1295 functions by promoting growth hormone release through its interaction with GHRH receptors, which should trigger the release of the complete family of growth hormone peptides typically secreted by the pituitary gland. These hormones will contribute to increased bone density, collagen production, and immune system support, along with stimulating the development of lean muscle mass.

 

CJC-1295 with DAC can be combined with growth hormone-releasing peptides to enhance the results of peptide cycling. It is frequently used in conjunction with growth hormone replacement peptides (GHRP) like GHRP-6 or GHRP-2. The combined application of CJC-1295 DAC and GHRPs will expedite fat loss and weight reduction while fostering anabolic effects through growth hormone-induced fat breakdown. Overall, CJC-1295 with DAC will enhance protein synthesis and promote the growth of lean muscle tissue. The peptide also aids in faster recovery from injuries, reduces body fat, and increases muscle mass. The growth-promoting characteristics of CJC-1295 DAC will further stimulate cell growth and division, improving skin health, healing, and immune system performance.

 

It is important not to confuse this peptide with CJC-1295 without DAC, as their chemical properties differ significantly, which influences dosing. CJC-1295 DAC has a half-life of approximately 8 days post-injection. CJC-1295 with DAC is typically administered subcutaneously and can be injected weekly at doses of 100 mcg or 200 mcg due to its long half-life. This CJC-1295 DAC peptide cycling method allows for a sustained elevation in growth hormone levels. A weekly injection of CJC-1295 with DAC can also be stacked with other GHRPs, such as GHRP-6 or GHRP-2.

 

Numerous studies have documented the growth-enhancing effects and safety of GHRH when administered to children with growth hormone deficiencies. Various treatment protocols, including intravenous pulses, intranasal delivery, subcutaneous injections, and continuous infusion, have been evaluated, demonstrating that the growth-promoting effect of GHRH correlates with the dosage and frequency of administration. No unexpected adverse effects have been reported after extended treatment, regardless of the delivery method. However, minor side effects, such as tiredness, a feeling of euphoria (head rush), water retention, tingling, and numbness, may occur. Adhering to the recommended dosage will help minimize the risk of side effects.